How to navigate into the emerging landscape of HER2-low breast cancer? The ESMO Expert Consensus statements on the definition, diagnosis, and management of HER2-low breast cancer aim to address major controversies stemming from recent research in the field.
Fine-tuning of the HER2-low pathologic diagnosis, along with accumulation of more clinical data in the field, will help to fully unlock the benefit of novel anti-HER2 antibody-drug conjugates in the coming years and possibly inform the targeting of HER2-low expression in tumour types beyond breast cancer.
Full publication: https://www.annalsofoncology.org/article/S0923-7534(23)00693-2/fulltext
The ESMO Expert Consensus Statement series of publications contain recommendations on well-defined, controversial or clinically-relevant topics and are produced by 20-40 key experts in the field. You can find the full list of publications here: https://www.esmo.org/guidelines/esmo-expert-consensus-statements
Produced by the European Society for Medical Oncology
http://www.esmo.org
